ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,125
0,00%
Bitcoin
64 194,99
0,31%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. VistaGen Therapeutics Inc (VTGN)

  7. VistaGen Therapeutics Inc (VTGN) Actualités

VTGN VistaGen Therapeutics Inc

4,55
0,14 (3,17%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
VistaGen Therapeutics Inc VTGN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,14 3,17% 4,55 06:00:08
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,47 4,31 4,55 4,50 4,41
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202414:30BWVistagen Announces Positive Results from Phase 2A Pilot..
09/4/202414:30BWVistagen to Present at the 2024 Anxiety and Depression..
01/4/202414:30BWVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol..
11/3/202413:30BWVistagen to Present at Stifel 2024 Virtual CNS Days
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/2/202414:30BWVistagen to Present at TD Cowen 44th Annual Health Care..
15/2/202400:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:52EDGAR2Form S-3 - Registration statement under Securities Act of..
13/2/202422:33EDGAR2Form 8-K - Current report
13/2/202422:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202422:20BWVistagen Reports Fiscal 2024 Third Quarter Financial Results..
06/2/202414:30BWVistagen to Report Fiscal Year 2024 Third Quarter Financial..
03/1/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:09EDGAR2Form 8-K - Current report
27/12/202314:30BWVistagen Receives Notice from European Patent Office of..
09/11/202322:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:42EDGAR2Form 8-K - Current report
09/11/202322:30BWVistagen Provides Corporate Update and Reports Fiscal 2024..
08/11/202314:30BWVistagen to Present at Stifel 2023 Healthcare Conference
07/11/202314:30BWVistagen to Present Positive Fasedienol Phase 3 Data and..
07/11/202303:46EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202322:27EDGAR2Form 8-K - Current report
06/11/202314:00BWVistagen To Report Second Quarter Financial Results and Host..
04/11/202301:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/10/202322:13EDGAR2Form 8-K - Current report
16/10/202322:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/10/202322:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/10/202322:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/10/202314:30BWVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro..
04/10/202322:07EDGAR2Form 8-K - Current report
03/10/202322:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202313:30BWVistagen Announces Pricing of $100 Million Underwritten..
02/10/202313:15EDGAR2Form 8-K - Current report
29/9/202322:26EDGAR2Form 8-K - Current report
12/9/202314:30BWVistagen Announces Positive Results from Exploratory Phase..
08/9/202323:27EDGAR2Form 8-K - Current report
05/9/202315:00BWVistagen and Fuji Enter Exclusive Negotiation Agreement for..
23/8/202319:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202319:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202314:40EDGAR2Form 8-K - Current report
22/8/202314:30BWVistagen Appoints Cindy Anderson as Chief Financial Officer

Dernières Valeurs Consultées

NASDAQ
VTGN
VistaGen Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés